University of Iowa Hospitals and Clinics, Iowa City, United States.
Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, Uttar Pradesh, India.
Anaesthesiol Intensive Ther. 2021;53(5):429-439. doi: 10.5114/ait.2021.110607.
Direct oral anticoagulants (DOACs) have revolutionized the field of anticoagulation in the last decade, mainly due to their fixed dosing, rapid onset of anticoagulant effect, and non-inferiority to vitamin K antagonists for both efficacy and safety. Also, the availability of specific and non-specific reversal agents makes these drugs popular. However, in critically ill patients, significant alterations in drug pharmacokinetics and pharmacodynamics might occur due to various ongoing pathophysiological derangements like decreased gastrointestinal absorption, increased volume of distribution, and impaired renal and/or hepatic function. Insight into these changes is essential regarding the safe and effective use of DOACs in critically ill patients. The current article is a narrative review on the use of DOACs in intensive care unit patients, covering 'Applied pharmacology'; the second article in the series covers 'Clinical evidence'.
直接口服抗凝剂 (DOACs) 在过去十年中彻底改变了抗凝领域,主要是因为它们固定剂量、抗凝效果迅速起效,并且在疗效和安全性方面与维生素 K 拮抗剂相当。此外,特异性和非特异性逆转剂的可用性也使这些药物广受欢迎。然而,在危重病患者中,由于各种持续的病理生理紊乱,如胃肠道吸收减少、分布容积增加以及肾功能和/或肝功能受损,药物药代动力学和药效学可能会发生显著变化。了解这些变化对于在危重病患者中安全有效地使用 DOACs 至关重要。本文是一篇关于 DOAC 在重症监护病房患者中应用的叙述性综述,涵盖了“应用药理学”;该系列的第二篇文章涵盖了“临床证据”。